Therapeutic perspectives for prion diseases in humans and animals
Rebeca Benavente,Rodrigo Morales
DOI: https://doi.org/10.1371/journal.ppat.1012676
IF: 7.464
2024-12-11
PLoS Pathogens
Abstract:Prion diseases are a group of fatal neurodegenerative disorders affecting several mammals including humans, cattle, cervids, sheep, goats, and others [1–3]. These diseases are driven by the misfolding of the cellular prion protein (PrP C ) into β-sheet rich structures. The disease-associated prion, termed PrP Sc , is prone to aggregation as well as neurotoxic [4–6]. Prion diseases can be associated with mutations in the prion protein gene ( PRNP ), induced by the exposure to prion-contaminated materials, or arise sporadically [3,7]. A relevant area of research in the prion field is drug discovery. Despite many efforts spanning decades, prion diseases still have no significant modifying treatments or cures [1,2,7–10]. Several factors affect the development of effective anti-prion treatments including the different conformations that PrP Sc particles acquire (also known as prion strains [7,11]), the limited number of prion strains that are available to be studied in cell-culture models [1], the rare incidence of human prion diseases that limit patient recruitment, and the still elusive understanding of prion pathogenesis, among others [7,12]. Moreover, the lack of sensitive detection methods to identify the disease in its early stages [13] makes it hard to treat individuals before the onset of symptoms when brain damage is already extensive and likely irreversible [3]. This article focuses on the different approaches used to develop anti-prion therapies targeting PrP C , PrP Sc , and associated pathological pathways. We also discuss methods that have been employed in the field to develop and evaluate new therapies. Finally, we discuss some therapeutic strategies tested in humans and animals, as well as future perspectives for therapies against prion diseases.
microbiology,virology,parasitology